法尼酯X受体在脂质代谢过程中的调控作用

法尼酯X受体(Farnesoid X Receptor,FXR)属于配体依赖的核转录因子,可被内源性配体胆汁酸激活,通过调节胆汁酸、胆固醇、脂蛋白及脂肪酸代谢维持血浆中脂质的稳态,从而达到调节脂质代谢的目的。最近研究发现FXR在脉管系统中也有表达活性,开辟了FXR调节脂质代谢的新途径。随着新配体及靶基因的发现,研究FXR的作用机制以及寻找对脂质代谢具有调控作用的FXR的配体,对于脂代谢异常和动脉粥样硬化的防治具有重要意义。本文综述了该领域的最新进展。     

类法尼醇X受体对脂代谢的调控作用

类法尼醇X受体（famesoid X receptor,FXR）属于于配体激活的核转录因子,是核受体超家族中的一员。受配体激活后．FXR在胆汁酸、脂质代谢中具有重要调控作用。随着FXR特异性配体及拮抗剂的发现,其在代谢及相关疾病中的调控作用日趋明显。最近发现,FXR在心血管系统中有表达活性,开辟了FXR调控网络的新领域。     

胆汁酸受体FXR 的研究进展

法尼酯衍生物X受体(FXR)是一种胆汁酸受体,在胆汁酸代谢和胆固醇代谢中发挥重要作用,并有望成为降低胆固醇,治疗某些心血管病及肝脏疾病的治疗靶点。本文介绍了FXR的发现、FXR在调控胆汁酸和脂质代谢中的作用,以及FXR在心血管疾病治疗中的应用前景。     

肝X受体的研究进展

肝X受体（liver Xreceptors,LXRs）作为一种氧化型固醇激活的核受体,调控胆固醇代谢过程中一些关键基因的表达,是机体的胆固醇代谢感受器。另外,LXRs还参与调节机体其他生理活动,包括脂肪形成、糖代谢、巨噬细胞的天然免疫和炎症反应等。因此,LXRs有望作为治疗动脉粥样硬化、高胆固醇血症、2型糖尿病等的药物靶点。     

肝X受体的研究进展

肝X受体(liver X receptors, LXRs)作为一种氧化型固醇激活的核受体,调控胆固醇代谢过程中一些关键基因的表达,是机体的胆固醇代谢感受器.另外,LXRs还参与调节机体其他生理活动,包括脂肪形成、糖代谢、巨噬细胞的天然免疫和炎症反应等.因此,LXRs有望作为治疗动脉粥样硬化、高胆固醇血症、2型糖尿病等的药物靶点.     

肝脂酶研究概况

肝脂酶研究概况余瑞元胡艳（北京大学生物化学及分子生物学系，北京１００８７１）关键词肝脂酶１．肝脂酶的发现Ｈａｈｎ首先观察到，对患高血脂症的狗进行静脉注射肝素，即引起患狗混浊的血浆变清，这是由于一种具有脂解活性的酶从组织的肝素结合位点上释放到血液中所致...     

肝X受体对动脉粥样硬化的调节

脂代谢异常和炎症反应是动脉粥样硬化形成的主要原因,肝X受体可以调节脂代谢中一组关键蛋白以及天然免疫应答中一些炎性介质的表达,来增强脂类代谢,抑制炎症发生,从而阻碍动脉粥化。     

肝X受体调控非泡沫细胞对动脉粥样硬化的作用

肝X受体(liver X receptor,LXR)是体内代谢的关键调节因子之一,该因子转录活性受氧化型胆固醇调控。多项研究表明,LXR及其靶基因调节体内的甾醇和脂肪酸稳态,与动脉粥样硬化(atherosclerosis,AS)的发生发展联系密切。LXR有望作为治疗AS的靶点,除了通过调控巨噬细胞源性的泡沫细胞发挥抑制炎症及促进胆固醇的逆向转运等作用外,还对血管细胞及造血细胞有重要的调节作用。本文就LXR调控非泡沫细胞抗AS的分子机制展开综述,期望为AS的防治提供新的靶点和途径。     

激活类法尼醇X核内受体（FXR）可下调载脂蛋白M在HepG2细胞中的表达

类法尼醇X核内受体（farnesoid X receptor, FXR）和载脂蛋白M(ApoM)在动脉粥样硬化中发挥重要作用．为研究FXR激动剂鹅脱氧胆酸(chenodexycholic acid, CDCA)和拮抗剂Guggulsterones在人肝癌细胞株HepG2和人胎肝细胞株L02中对载脂蛋白M(apolipoprotein M, ApoM)表达的影响．本研究应用逆转录 聚合酶链反应（RT PCR）法和Western印迹法检测CDCA和CDCA加Guggulsterones处理后HepG2和L02细胞中ApoM的mRNA水平和HepG2细胞中ApoM的蛋白水平．实验结果显示：FXR天然配体CDCA以剂量依赖的方式显著降低HepG2细胞中ApoM分子（mRNA和蛋白水平）的表达,L02细胞中ApoM分子mRNA水平的表达;FXR抑制剂Guggulsterones不仅能明显阻止CDCA对ApoM表达的下调,而且可引起ApoM表达显著增加．本研究提示,FXR抑制剂Guggulsterones在抗动脉粥样硬化过程中可能发挥重要作用．     

核受体FXR:一种新型代谢调节因子

法尼酯衍生物X受体(farnesoid X receptor,FXR)是一种胆汁酸受体,属于核受体超家族成员。FXR通过调控一系列基因的表达,在胆汁酸、脂质和糖代谢中发挥重要作用,进而有望成为治疗一系列代谢性疾病的药物靶点。本文将就FXR的相关研究进展作一综述。     

激活FXR抑制结肠癌细胞浸润转移及MMP-7的表达

目的:探讨法尼酯X受体(FXR)特异性激动剂GW4064抑制结肠癌细胞浸润转移的机制。方法:在体外培养人结肠癌细胞HT-29,应用GW4064作用于结肠癌细胞,以四唑氮蓝还原法(MTT)检测细胞活性的变化。用transwell小室研究结肠癌细胞的迁移及浸润。用RT-PCR检测FXRm RNA及MMP-7mRNA表达的变化,用western blot检测FXR及MMP-7蛋白表达的变化。结果:MTT结果显示GW4064作用于人结直肠HT-29细胞的生长抑制率呈浓度依赖性;transwell小室结果显示GW4064抑制结肠癌细胞的浸润转移,与对照组相比,差异具有统计学意义(P0.05),RT-PCR及Western blot显示GW4064促进FXR m RNA及蛋白表达,抑制MMP-7mRNA及蛋白的表达,与对照组相比差异有统计学意义(P0.05)。结论:GW4064抑制结肠癌细胞的生长及转移,上调HT-29细胞FXR m RNA及蛋白的表达,下调HT-29细胞MMP-7 m RNA及蛋白的表达。FXR被激活后抑制结肠癌细胞转移,MMP-7可能是其作用通路之一。     

Farnesoid X Receptor, through the Binding with Steroidogenic Factor 1-responsive Element, Inhibits Aromatase Expression in Tumor Leydig Cells

The farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that regulates bile acid homeostasis. It is expressed in the liver and the gastrointestinal tract, but also in several non-enterohepatic tissues including testis. Recently, FXR was identified as a negative modulator of the androgen-estrogen-converting aromatase enzyme in human breast cancer cells. In the present study we detected the expression of FXR in Leydig normal and tumor cell lines and in rat testes tissue. We found, in rat Leydig tumor cells, R2C, that FXR activation by the primary bile acid chenodeoxycholic acid (CDCA) or a synthetic agonist GW4064, through a SHP-independent mechanism, down-regulates aromatase expression in terms of mRNA, protein levels, and its enzymatic activity. Transient transfection experiments, using vector containing rat aromatase promoter PII, evidenced that CDCA reduces basal aromatase promoter activity. Mutagenesis studies, electrophoretic mobility shift, and chromatin immunoprecipitation analysis reveal that FXR is able to compete with steroidogenic factor 1 in binding to a common sequence present in the aromatase promoter region interfering negatively with its activity. Finally, the FXR-mediated anti-proliferative effects exerted by CDCA on tumor Leydig cells are at least in part due to an inhibition of estrogen-dependent cell growth. In conclusion our findings identify for the first time the activators of FXR as negative modulators of the aromatase enzyme in Leydig tumor cell lines.     

Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice

Activation of the farnesoid X receptor (FXR) has indicated a therapeutic potential for this nuclear bile acid receptor in the prevention of diabetic nephropathy and obesity-induced renal damage. Here, we investigated the protective role of FXR against kidney damage induced by obesity in mice that had undergone uninephrectomy, a model resembling the clinical situation of kidney donation by obese individuals. Mice fed a high-fat diet developed the core features of metabolic syndrome, with subsequent renal lipid accumulation and renal injury, including glomerulosclerosis, interstitial fibrosis, and albuminuria. The effects were accentuated by uninephrectomy. In human renal biopsies, staining of 4-hydroxynonenal (4-HNE), glucose-regulated protein 78 (Grp78), and C/EBP-homologous protein, markers of endoplasmic reticulum stress, was more prominent in the proximal tubules of 15 obese patients compared with 16 non-obese patients. In mice treated with the FXR agonist obeticholic acid, renal injury, renal lipid accumulation, apoptosis, and changes in lipid peroxidation were attenuated. Moreover, disturbed mitochondrial function was ameliorated and the mitochondrial respiratory chain recovered following obeticholic acid treatment. Culturing renal proximal tubular cells with free fatty acid and FXR agonists showed that FXR activation protected cells from free fatty acid-induced oxidative stress and endoplasmic reticulum stress, as denoted by a reduction in the level of reactive oxygen species staining and Grp78 immunostaining, respectively. Several genes involved in glutathione metabolism were induced by FXR activation in the remnant kidney, which was consistent with a decreased glutathione disulfide/glutathione ratio. In summary, FXR activation maintains endogenous glutathione homeostasis and protects the kidney in uninephrectomized mice from obesity-induced injury.     

核受体FXR调控SHP的机制及FXR-SHP轴在肝脏中作用的研究进展

法尼醇X受体(Farnesoid X Receptor,FXR)属于代谢性核受体,是需配体激活的转录因子,在肝脏胆汁酸、脂质代谢过程,肝脏炎症和肿瘤的发展过程中起着重要的调节作用。小异二聚体伴侣受体(Small Heterodimer Partner,SHP)是核受体超家族中的一个特殊成员,在特异的组织中作为转录调节的共抑制因子,抑制其他多种转录因子的活性,在众多代谢通路中起到了负性调节作用。近年来研究发现,核受体FXR通过对SHP的调控来实现其在肝脏的多种功能。本文着重对FXR调节SHP的机制及FXR-SHP轴在肝脏中作用进行综述。